Abstract
Although it is well established that aluminum (Al) is neurotoxic, the potential role of this element in the etiology of Alzheimers disease (AD) is not well established. In this study, we evaluated the effects of oral Al exposure on spatial learning, memory and neurogenesis in Tg2576 mice, an animal model of AD in which Abeta plaques start to be deposited at 9 months of age. Aluminum was given as Al lactate (11 mg/g of food) for 6 months. At 11 months of age a water maze test was carried out to evaluate learning and memory. Subsequently, mice were injected with bromodeoxyuridine (BrdU) and sacrificed 24 hours or 28 days after the last injection in order to assess proliferation, survival and differentiation of neurons. We observed impaired acquisition in the water maze task in Al-treated Tg2576 mice, as well as worse memory in the Al-exposed groups. In terms of neurogenesis, no effects of aluminum were observed in proliferation, survival and differentiation. The results of this investigation suggest that Tg2576 mice fed for 210 days with rodent chow supplemented with Al lactate at 11 mg/g of food have impaired spatial learning although their neurogenesis remains unmodified.
Keywords: Alzheimer disease, aluminum, Tg2576 mice, β-amyloid, spatial learning, hippocampus, proliferation, neurobehavior
Current Alzheimer Research
Title: Impaired Spatial Learning and Unaltered Neurogenesis in a Transgenic Model of Alzheimers Disease After Oral Aluminum Exposure
Volume: 7 Issue: 5
Author(s): D. Ribes, M.T. Colomina, P. Vicens and J.L. Domingo
Affiliation:
Keywords: Alzheimer disease, aluminum, Tg2576 mice, β-amyloid, spatial learning, hippocampus, proliferation, neurobehavior
Abstract: Although it is well established that aluminum (Al) is neurotoxic, the potential role of this element in the etiology of Alzheimers disease (AD) is not well established. In this study, we evaluated the effects of oral Al exposure on spatial learning, memory and neurogenesis in Tg2576 mice, an animal model of AD in which Abeta plaques start to be deposited at 9 months of age. Aluminum was given as Al lactate (11 mg/g of food) for 6 months. At 11 months of age a water maze test was carried out to evaluate learning and memory. Subsequently, mice were injected with bromodeoxyuridine (BrdU) and sacrificed 24 hours or 28 days after the last injection in order to assess proliferation, survival and differentiation of neurons. We observed impaired acquisition in the water maze task in Al-treated Tg2576 mice, as well as worse memory in the Al-exposed groups. In terms of neurogenesis, no effects of aluminum were observed in proliferation, survival and differentiation. The results of this investigation suggest that Tg2576 mice fed for 210 days with rodent chow supplemented with Al lactate at 11 mg/g of food have impaired spatial learning although their neurogenesis remains unmodified.
Export Options
About this article
Cite this article as:
Ribes D., Colomina M.T., Vicens P. and Domingo J.L., Impaired Spatial Learning and Unaltered Neurogenesis in a Transgenic Model of Alzheimers Disease After Oral Aluminum Exposure, Current Alzheimer Research 2010; 7 (5) . https://dx.doi.org/10.2174/156720510791383840
DOI https://dx.doi.org/10.2174/156720510791383840 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Premature Aging in Fibromyalgia
Current Aging Science Dehydroepiandrosterone and Its Derivatives: Potentially Novel Anti-Proliferative and Chemopreventive Agents
Current Pharmaceutical Design Amorphous and Crystalline Particulates: Challenges and Perspectives in Drug Delivery
Current Pharmaceutical Design Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model
Current Alzheimer Research Meet Our Editorial Board Member
Current Molecular Pharmacology Discovery of New Medication for the Treatment of Depression Comorbid with Inflammatory Diseases
Current Topics in Medicinal Chemistry 3D-QSAR in Drug Design - A Review
Current Topics in Medicinal Chemistry Targeting Insulin Signaling for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Regulation of Neurogenesis and Angiogenesis in Depression
Current Neurovascular Research Cocaine and Acute Vascular Diseases
Current Drug Abuse Reviews The Remote Monitoring of Smoking in Adolescents
Adolescent Psychiatry Practical Considerations in the Development of Hemoglobin-Based Oxygen Therapeutics
Current Drug Discovery Technologies Melatonin Metabolism in the Central Nervous System
Current Neuropharmacology Drug Abuse, Brain Calcification and Glutamate-Induced Neurodegeneration
Current Drug Abuse Reviews PKC Delta and Epsilon in Drug Targeting and Therapeutics
Recent Patents on DNA & Gene Sequences Therapies in Development for Non-Infectious Uveitis
Current Molecular Medicine Mood Charting and Technology: New Approach to Monitoring Patients with Mood Disorders
Current Psychiatry Reviews The Role of the Anti-Amyloidogenic Secretase ADAM10 in Shedding the APP-like Proteins
Current Alzheimer Research Amyloidogenicity and Aggregate Cytotoxicity of Human Glucagon-Like Peptide-1 (hGLP-1)
Protein & Peptide Letters Aβ1-40 and Aβ1-42 Plasmatic Levels In Stroke: Influence of Pre-Existing Cognitive Status and Stroke Characteristics#
Current Alzheimer Research